Sabina A. Murphy
Oslo University Hospital
3 papers in the Anchorcite directory, published between 2007 and 2018, cited 19,788 times in total.
ORCID profileResearch topics
- Acute Myocardial Infarction Research · 2 papers
- Antiplatelet Therapy and Cardiovascular Diseases · 1 paper
- Coronary Interventions and Diagnostics · 1 paper
- Diabetes Treatment and Management · 1 paper
- Chronic Kidney Disease and Diabetes · 1 paper
- Heart Failure Treatment and Management · 1 paper
Frequent co-authors
- Stephen D. Wiviott · 3 papers
- Julia Kuder · 2 papers
- Marc Steven Sabatine · 2 papers
- Eugene Braunwald · 1 paper
- Carolyn H. McCabe · 1 paper
- Gilles Montalescot · 1 paper
- Witold Rużyłło · 1 paper
- Shmuel Gottlieb · 1 paper
Papers
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine · 2007 · 6,831 citations
BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with…
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine · 2018 · 6,600 citations
BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS: of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes)…
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine · 2017 · 6,357 citations
BACKGROUND: Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving…
Metadata from OpenAlex (CC0).